drugset / Trial / NCT02734966

Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

NCT02734966

Phase 2 Completed 174 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.

Timeline

Start
2007-12
Primary completion
2008-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Isoglycyrrhizinate Unknown 100 mg
Subject Magnesium Isoglycyrrhizinate Unknown 200 mg
Comparator Tiopronin Small molecule 200 mg